Selected research
Industry Research
Blood Lipid Control Products Industry Research Report 2026
Market perspective
The global Blood Lipid Control Products market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Blood Lipid Control Products is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Blood Lipid Control Products is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Blood Lipid Control Products is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Blood Lipid Control Products include Abbott, Lumigenex, GeneWell Bio Tech, Sinocare, Mindray Medical, BGI Group, URIT Medical Electronic, Beijing Strong Biotechnologies and Thermo Fisher, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Blood Lipid Control Products market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Blood Lipid Control Products Market by Company
Abbott
Lumigenex
GeneWell Bio Tech
Sinocare
Mindray Medical
BGI Group
URIT Medical Electronic
Beijing Strong Biotechnologies
Thermo Fisher
Sekisui Medical
Randox
MP Biomedicals
Bio-Rad
Blood Lipid Control Products Segment by Type
Human Serum Matrix
Animal Serum Matrix
Blood Lipid Control Products Segment by Application
Laboratory
Hospital
Pharmaceutical
Others
Blood Lipid Control Products Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Lipid Control Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Blood Lipid Control Products and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Lipid Control Products.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Blood Lipid Control Products manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Blood Lipid Control Products by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Blood Lipid Control Products in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Human Serum Matrix
- Animal Serum Matrix
Applications
- Laboratory
- Hospital
- Pharmaceutical
- Others
Companies covered
- Abbott
- Lumigenex
- GeneWell Bio Tech
- Sinocare
- Mindray Medical
- BGI Group
- URIT Medical Electronic
- Beijing Strong Biotechnologies
- Thermo Fisher
- Sekisui Medical
- Randox
- MP Biomedicals
- Bio-Rad
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Blood Lipid Control Products Market Size (2021-2032)
- 2.2.2 Global Blood Lipid Control Products Sales (2021-2032)
- 2.2.3 Global Blood Lipid Control Products Market Average Price (2021-2032)
- 2.3 Blood Lipid Control Products by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Human Serum Matrix
- 2.3.3 Animal Serum Matrix
- 2.4 Blood Lipid Control Products by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Laboratory
- 2.4.3 Hospital
- 2.4.4 Pharmaceutical
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Blood Lipid Control Products Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Blood Lipid Control Products Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Blood Lipid Control Products Revenue of Manufacturers (2021-2026)
- 3.4 Global Blood Lipid Control Products Average Price by Manufacturers (2021-2026)
- 3.5 Global Blood Lipid Control Products Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Blood Lipid Control Products, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Blood Lipid Control Products, Product Type & Application
- 3.8 Global Manufacturers of Blood Lipid Control Products, Established Date
- 3.9 Global Blood Lipid Control Products Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott
- 4.1.1 Abbott Company Information
- 4.1.2 Abbott Business Overview
- 4.1.3 Abbott Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Blood Lipid Control Products Product Portfolio
- 4.1.5 Abbott Recent Developments
- 4.2 Lumigenex
- 4.2.1 Lumigenex Company Information
- 4.2.2 Lumigenex Business Overview
- 4.2.3 Lumigenex Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Lumigenex Blood Lipid Control Products Product Portfolio
- 4.2.5 Lumigenex Recent Developments
- 4.3 GeneWell Bio Tech
- 4.3.1 GeneWell Bio Tech Company Information
- 4.3.2 GeneWell Bio Tech Business Overview
- 4.3.3 GeneWell Bio Tech Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GeneWell Bio Tech Blood Lipid Control Products Product Portfolio
- 4.3.5 GeneWell Bio Tech Recent Developments
- 4.4 Sinocare
- 4.4.1 Sinocare Company Information
- 4.4.2 Sinocare Business Overview
- 4.4.3 Sinocare Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sinocare Blood Lipid Control Products Product Portfolio
- 4.4.5 Sinocare Recent Developments
- 4.5 Mindray Medical
- 4.5.1 Mindray Medical Company Information
- 4.5.2 Mindray Medical Business Overview
- 4.5.3 Mindray Medical Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mindray Medical Blood Lipid Control Products Product Portfolio
- 4.5.5 Mindray Medical Recent Developments
- 4.6 BGI Group
- 4.6.1 BGI Group Company Information
- 4.6.2 BGI Group Business Overview
- 4.6.3 BGI Group Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 BGI Group Blood Lipid Control Products Product Portfolio
- 4.6.5 BGI Group Recent Developments
- 4.7 URIT Medical Electronic
- 4.7.1 URIT Medical Electronic Company Information
- 4.7.2 URIT Medical Electronic Business Overview
- 4.7.3 URIT Medical Electronic Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 URIT Medical Electronic Blood Lipid Control Products Product Portfolio
- 4.7.5 URIT Medical Electronic Recent Developments
- 4.8 Beijing Strong Biotechnologies
- 4.8.1 Beijing Strong Biotechnologies Company Information
- 4.8.2 Beijing Strong Biotechnologies Business Overview
- 4.8.3 Beijing Strong Biotechnologies Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Beijing Strong Biotechnologies Blood Lipid Control Products Product Portfolio
- 4.8.5 Beijing Strong Biotechnologies Recent Developments
- 4.9 Thermo Fisher
- 4.9.1 Thermo Fisher Company Information
- 4.9.2 Thermo Fisher Business Overview
- 4.9.3 Thermo Fisher Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Thermo Fisher Blood Lipid Control Products Product Portfolio
- 4.9.5 Thermo Fisher Recent Developments
- 4.10 Sekisui Medical
- 4.10.1 Sekisui Medical Company Information
- 4.10.2 Sekisui Medical Business Overview
- 4.10.3 Sekisui Medical Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sekisui Medical Blood Lipid Control Products Product Portfolio
- 4.10.5 Sekisui Medical Recent Developments
- 4.11 Randox
- 4.11.1 Randox Company Information
- 4.11.2 Randox Business Overview
- 4.11.3 Randox Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Randox Blood Lipid Control Products Product Portfolio
- 4.11.5 Randox Recent Developments
- 4.12 MP Biomedicals
- 4.12.1 MP Biomedicals Company Information
- 4.12.2 MP Biomedicals Business Overview
- 4.12.3 MP Biomedicals Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 MP Biomedicals Blood Lipid Control Products Product Portfolio
- 4.12.5 MP Biomedicals Recent Developments
- 4.13 Bio-Rad
- 4.13.1 Bio-Rad Company Information
- 4.13.2 Bio-Rad Business Overview
- 4.13.3 Bio-Rad Blood Lipid Control Products Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Bio-Rad Blood Lipid Control Products Product Portfolio
- 4.13.5 Bio-Rad Recent Developments
5 Global Blood Lipid Control Products Market Scenario by Region
- 5.1 Global Blood Lipid Control Products Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Blood Lipid Control Products Sales by Region: 2021-2032
- 5.2.1 Global Blood Lipid Control Products Sales by Region: 2021-2026
- 5.2.2 Global Blood Lipid Control Products Sales by Region: 2027-2032
- 5.3 Global Blood Lipid Control Products Revenue by Region: 2021-2032
- 5.3.1 Global Blood Lipid Control Products Revenue by Region: 2021-2026
- 5.3.2 Global Blood Lipid Control Products Revenue by Region: 2027-2032
- 5.4 North America Blood Lipid Control Products Market Facts & Figures by Country
- 5.4.1 North America Blood Lipid Control Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Blood Lipid Control Products Sales by Country (2021-2032)
- 5.4.3 North America Blood Lipid Control Products Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Blood Lipid Control Products Market Facts & Figures by Country
- 5.5.1 Europe Blood Lipid Control Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Blood Lipid Control Products Sales by Country (2021-2032)
- 5.5.3 Europe Blood Lipid Control Products Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Blood Lipid Control Products Market Facts & Figures by Country
- 5.6.1 Asia Pacific Blood Lipid Control Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Blood Lipid Control Products Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Blood Lipid Control Products Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Blood Lipid Control Products Market Facts & Figures by Country
- 5.7.1 South America Blood Lipid Control Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Blood Lipid Control Products Sales by Country (2021-2032)
- 5.7.3 South America Blood Lipid Control Products Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Blood Lipid Control Products Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Blood Lipid Control Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Blood Lipid Control Products Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Blood Lipid Control Products Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Blood Lipid Control Products Sales by Type (2021-2032)
- 6.1.1 Global Blood Lipid Control Products Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Blood Lipid Control Products Sales Market Share by Type (2021-2032)
- 6.2 Global Blood Lipid Control Products Revenue by Type (2021-2032)
- 6.2.1 Global Blood Lipid Control Products Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Blood Lipid Control Products Revenue Market Share by Type (2021-2032)
- 6.3 Global Blood Lipid Control Products Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Blood Lipid Control Products Sales by Application (2021-2032)
- 7.1.1 Global Blood Lipid Control Products Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Blood Lipid Control Products Sales Market Share by Application (2021-2032)
- 7.2 Global Blood Lipid Control Products Revenue by Application (2021-2032)
- 7.2.1 Global Blood Lipid Control Products Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Blood Lipid Control Products Revenue Market Share by Application (2021-2032)
- 7.3 Global Blood Lipid Control Products Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Blood Lipid Control Products Value Chain Analysis
- 8.1.1 Blood Lipid Control Products Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Blood Lipid Control Products Production Mode & Process
- 8.2 Blood Lipid Control Products Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Blood Lipid Control Products Distributors
- 8.2.3 Blood Lipid Control Products Customers
9 Global Blood Lipid Control Products Analyzing Market Dynamics
- 9.1 Blood Lipid Control Products Industry Trends
- 9.2 Blood Lipid Control Products Industry Drivers
- 9.3 Blood Lipid Control Products Industry Opportunities and Challenges
- 9.4 Blood Lipid Control Products Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst